Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Merck
Colorcon
UBS
Chubb
Chinese Patent Office
Cantor Fitzgerald
Express Scripts
Baxter

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,569,325

« Back to Dashboard

Which drugs does patent 8,569,325 protect, and when does it expire?

Patent 8,569,325 protects EFFIENT and is included in one NDA.

Protection for EFFIENT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty patent family members in twenty-six countries.
Summary for Patent: 8,569,325
Title:Method of treatment with coadministration of aspirin and prasugrel
Abstract: A method for the prevention of diseases caused by thrombus or embolus. The method is to separately administer 2-acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahyd- rothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, in their pharmacologically effective amounts, to a warm-blooded animal.
Inventor(s): Asai; Fumitoshi (Nishitokyo, JP), Sugidachi; Atsuhiro (Kawasaki, JP), Ogawa; Taketoshi (Tokyo, JP), Inoue; Teruhiko (Ube, JP)
Assignee: Daiichi Sankyo Company, Limited (Tokyo, JP) Ube Industries, Ltd. (Yamaguchi, JP)
Application Number:12/006,546
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,569,325
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,569,325

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eli Lilly And Co EFFIENT prasugrel hydrochloride TABLET;ORAL 022307-001 Jul 10, 2009 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Eli Lilly And Co EFFIENT prasugrel hydrochloride TABLET;ORAL 022307-002 Jul 10, 2009 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,569,325

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2000-392983Dec 25, 2000

Non-Orange Book US Patents Family Members for Patent 8,569,325

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,404,703 Medicinal compositions containing aspirin ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Accenture
McKesson
Covington
US Department of Justice
Mallinckrodt
Cerilliant
Chubb
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.